BR112021012496A2 - Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica - Google Patents

Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica

Info

Publication number
BR112021012496A2
BR112021012496A2 BR112021012496A BR112021012496A BR112021012496A2 BR 112021012496 A2 BR112021012496 A2 BR 112021012496A2 BR 112021012496 A BR112021012496 A BR 112021012496A BR 112021012496 A BR112021012496 A BR 112021012496A BR 112021012496 A2 BR112021012496 A2 BR 112021012496A2
Authority
BR
Brazil
Prior art keywords
enterovirus
inactivating
nucleotide
amino acid
well
Prior art date
Application number
BR112021012496A
Other languages
English (en)
Inventor
Amit Raychoudhuri
Murthy Ella Krishna
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of BR112021012496A2 publication Critical patent/BR112021012496A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32361—Methods of inactivation or attenuation
    • C12N2770/32363—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica. a presente invenção se refere a um enterovírus d68 adaptado para se propagar em titulações elevadas em células vero, e método de adaptação destas. a presente invenção também descreve composição de vacina adequada compreendendo antígeno de enterovírus d68 inativado.
BR112021012496A 2018-12-29 2019-12-27 Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica BR112021012496A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841049814 2018-12-29
PCT/IN2019/050960 WO2020136683A1 (en) 2018-12-29 2019-12-27 Adaptation of enterovirus to vero cells and vaccine formulations thereof

Publications (1)

Publication Number Publication Date
BR112021012496A2 true BR112021012496A2 (pt) 2021-11-30

Family

ID=71126945

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021012496A BR112021012496A2 (pt) 2018-12-29 2019-12-27 Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica

Country Status (6)

Country Link
US (1) US20220160862A1 (pt)
EP (1) EP3906051A4 (pt)
CN (1) CN113329767A (pt)
BR (1) BR112021012496A2 (pt)
SG (1) SG11202106394PA (pt)
WO (1) WO2020136683A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
CN114717201A (zh) * 2021-04-17 2022-07-08 景均股份有限公司 适应vero细胞的肠道病毒D68、肠道病毒D68疫苗及其用途
EP4399525A1 (en) * 2021-09-10 2024-07-17 Takeda Vaccines, Inc. Immunofocus assay for determining the titer of dengue viruses
CN114990075B (zh) * 2022-04-20 2023-07-14 中国医学科学院医学生物学研究所 一株可适用于人用疫苗细胞基质培养的柯萨奇病毒a组10型疫苗株及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103228293A (zh) * 2010-11-30 2013-07-31 巴拉特生物技术国际有限公司 用于在哺乳动物中预防和治疗金迪普拉病毒感染的疫苗制剂
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10752966B2 (en) * 2015-04-24 2020-08-25 Washington University Methods and compositions for detection of enterovirus D68
US9938588B2 (en) 2015-06-05 2018-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for detecting Enterovirus D68
CN107449915A (zh) * 2017-07-17 2017-12-08 中国医学科学院医学生物学研究所 一种检测血清中抗ev‑d68病毒抗体的方法
WO2019155492A1 (en) * 2018-02-07 2019-08-15 Bharat Biotech International Limited A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用

Also Published As

Publication number Publication date
SG11202106394PA (en) 2021-07-29
EP3906051A1 (en) 2021-11-10
CN113329767A (zh) 2021-08-31
EP3906051A4 (en) 2022-09-28
US20220160862A1 (en) 2022-05-26
WO2020136683A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
BR112021012496A2 (pt) Enterovírus adaptado bem como seu método e processo de adaptação, sequências de nucleotídeo e aminoácido, método para inativar enterovírus e composição imunogênica
CO2018005265A2 (es) Vacunas de ácido nucleico para el virus varicela-zóster
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
EA201791633A1 (ru) Способ точной модификации растения посредством транзиентной экспрессии гена
CU20110206A7 (es) Moléculas de unión humanas capaces de neutralizar el virus de la influenza h3n2
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112014024094A2 (pt) vírus do herpes aviário recombinante, vacina multivalente, método para a vacinação de uma ave simultaneamente contra pelo menos dois patógenos, antissoro direcionado contra o vírus do herpes aviário, e kit de vacinação para a imunização de espécies de aves
BR112017011582A2 (pt) fibroblasto de embrião de galinha imortalizado, cultura de célula, métodos para preparação de um cef importalizado, para a replicação de um vetor viral aviário e para a preparação de uma vacina, e, vacina.
UY33897A (es) Inhibidores del virus de la hepatitis c
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
UY34066A (es) Inhibidores del virus de la hepatitis c
BR112016030326A2 (pt) ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv?
EA201071086A1 (ru) Усовершенствованный способ получения вакцинных антигенов вируса гриппа
CY1123849T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα
BR112014013972A8 (pt) inibidores de hcv nssa
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
PH12018501750A1 (en) Porcine reproductive and respiratory syndrome vaccine virus
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
CL2023002187A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino